Actively Recruiting
BE.Amycon Study at UZ Leuven Collecting Body Samples and Health Data from Adults with Amyloidosis
Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2026-02-27
505
Participants Needed
2
Research Sites
17 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are establishing the Belgian Amyloidosis Consortium BE.AMYCON to gather human body material HBM and clinical data from patients with amyloidosis. This observational study aims to improve understanding of amyloidosis by creating a biobank and a data registry that collects detailed patient information, disease characteristics, treatment plans, and outcomes over time. The study involves collecting and storing biological samples such as blood, urine, and tissue from patients with suspected or confirmed amyloidosis. Additionally, patient data including baseline demographics, disease presentation, treatments, and responses will be recorded. The biobank will store samples for up to 2 years, while the data registry will track patients for up to 10 years or until death, loss to follow-up, or withdrawal. Participants will provide informed consent and may contribute samples and clinical data during the study period. Researchers will monitor disease characteristics at diagnosis, treatment responses, survival times, and disease progression. This long-term collection of biological and clinical information aims to support future scientific research and improve treatment strategies for amyloidosis.
CONDITIONS
Brief Title
BE.Amycon Biobank & Data Registry UZ Leuven
Research Team
M
Michel Delforge
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
